Biological Neurology

Zilbrysq

Payments companies reported to CMS as associated with Zilbrysq. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.4Massociated payments (2023-2025)
2,696clinicians with associated payments
2companies reporting

By year

2023 $164K
2024 $719K
2025 $538K

Payments reported as associated with Zilbrysq, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $855K
Neuromuscular Medicine (Psychiatry & Neurology) $244K
Clinical Neurophysiology $88K
Family $57K
Nurse Practitioner $40K
Physician Assistant $20K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Zilbrysq

These are the largest totals companies reported as associated with Zilbrysq. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Michael Rosario-Prieto St Petersburg, FL Neuromuscular Medicine (Psychiatry & Neurology) $58,312.90
Nicholas Silvestri Buffalo, NY Neuromuscular Medicine (Psychiatry & Neurology) $49,519.05
Perry Shieh Los Angeles, CA Neurology (Psychiatry & Neurology) $47,720.33
Samir Macwan Rancho Mirage, CA Neuromuscular Medicine (Psychiatry & Neurology) $42,449.42
Joshua Alpers Chattanooga, TN Neuromuscular Medicine (Psychiatry & Neurology) $42,223.30
Jon Durrani Centerville, OH Neurology (Psychiatry & Neurology) $40,248.16
Eduardo De Sousa Moore, OK Neurology (Psychiatry & Neurology) $39,944.38
Miriam Freimer Columbus, OH Neurology (Psychiatry & Neurology) $35,901.00
Hannah Machemehl Arden, NC Neurology (Psychiatry & Neurology) $35,285.83
Sonia Caraballo-Cartagena Schaumburg, IL Neurology (Psychiatry & Neurology) $31,174.37

Prescribed Zilbrysq?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.